CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
bortezomibdrug
Likely dose
Not stated in record
Key inclusion· 9
  • ✓Histologically confirmed cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome
  • ✓Stage IB-IV disease
  • ✓Relapsed or refractory disease, or intolerant to ≥1 prior systemic therapy
  • ✓Measurable disease by imaging or clinical finding
Key exclusion· 7
  • ✕History of myelodysplastic syndromes
  • ✕Evidence of CNS disease
  • ✕Peripheral neuropathy ≥grade 2
  • ✕Hypersensitivity to bortezomib, boron, or mannitol

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00182637
NCT00182637Phase 2Completed
CompareCT.gov

A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)

Jonsson Comprehensive Cancer Center·interventional·Posted Sep 16, 2005·Updated Aug 3, 2020

In Brief

A Phase 2 clinical trial evaluating bortezomib for Lymphoma. Completed, enrolled 5 participants across 1 site.

Detailed Summary

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with relapsed or refractory cutaneous T-cell lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartJul 1, 2004
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 20.8 years ago

Interventions

bortezomibdrug